ASS1 deficiency is a dubious disease that belongs to the field of genetic metabolism, clinical performance is complex and often involves multisystemic congestion. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of ASS1 deficiencies require the development of individualized treatment programs, typically including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic diseases have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the lack of ASS1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.